Association between BMI and OS with immune checkpoint inhibitor therapy for SCLC
Analysis of data from the National Lung Screening Trial (NLST) trials, It was a randomized controlled trial conducted by the Lung Screening Study group (LSS) and the American College of Radiology Imaging Network (ACRIN) to determine whether screening for lung cancer with low-dose helical computed tomography (CT) reduces mortality from lung cancer in high-risk individuals relative to screening with chest radiography. Approximately 54,000 participants were enrolled between August 2002 and April 2004. Patients with SCLC previously treated with at least 1 line of systemic therapy, were included in these trials.
All analyses were conducted in R, version 3.4.3 (R Foundation for Statistical Computing), using the survival package.23 Statistical tests were 2-sided and a P value <.05 was considered statistically significant.
1. The primary outcome assessed was OS. To examine whether BMI is associated with survival outcomes in patients with small cell lung cancer treated with immune checkpoint inhibitors.
2. Clinically relevant confounding factors evaluated included patient’s age, sex, race (white/Asian/other), Eastern Cooperative Oncology Group performance status (scale ranges from 0 to 4, with 0 being fully functional and asymptomatic, and 4 being bedridden), smoker status (current, previous, or never), tumor histologic type (squamous or nonsquamous),Medical Complications
Dr. Jianya,Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University